ECE2020 Audio ePoster Presentations Endocrine-related Cancer (14 abstracts)
An Endocrine and metabolic interactomic approach to identify novel diagnostic/prognostic biomarkers and therapeutic targets in gliomas
Jesus Perez Gomez 1,2,3,4 , Antonio C. Fuentes-Fayos 1,2,3,4 , Marisa L. Gandía-González 5 , Alberto Cano-Rojas 6 , Cristóbal Blanco-Acevedo 7 , Eva M. Negro-Moral 7 , Álvaro Toledano 7 , Manuel J. Ramos 7 , Rosa M. Ortega-Salas 8 , Sebastián Cerdán 9 , Marisa L. García-Martín 10 , Raúl M. Luque 1,2,3,4 & Juan Solivera 1,7
1Maimonides Institute of Biomedical Research of Cordoba (IMIBIC), 14004 Cordoba, Spain; 2Reina Sofia University Hospital (HURS), 14004 Cordoba, Spain; 3Department of Cell Biology, Physiology and Immunology, University of Cordoba, 14004 Cordoba, Spain; 4CIBER Physiopathology of Obesity and Nutrition (CIBERobn), 14004 Cordoba, Spain; 5Department of Neurosurgery, Hospital Universitario La Paz, 28046 Madrid, Spain; 6High-Performance Data Mining Lab, Department of Computer Science at the Virginia Commonwealth University, 23284 Richmond, VA, United States; 7Department of Neurosurgery, Reina Sofía University Hospital (HURS), 14004 Cordoba, Spain; 8Pathology Department, Reina Sofía University Hospital, 14004 Cordoba, Spain; 9Instituto de Investigaciones Biomédicas Alberto Sols CSIC, 28029 Madrid, Spain; 10Centro Andaluz de Nanomedicina y Biotecnología (BIONAND), 29590 Malaga, Spain
Gliomas are a common tumor type that affects the glial cells with common features of malignant tumors such as aggressive invasiveness, malignant transformation and vascular proliferation through the central nervous system. Currently, standard therapeutic strategies to treat malignant gliomas are not efficient having alow-rate survival (~12 months). Hence, there is a clear necessity for the identification of novel diagnostic/prognostic tools and therapeutic strategies to manage and treat these devastatingtumor pathologies. In this sense, a relevant relationship between metabolic/endocrine factors and tumor development/progression has been widely reported since defects in endocrine and metabolic homeostasis underlie many common human diseases, including tumor progression. In this context, we carried out an interaction omics-based approach to identify potential endocrine/metabolic biomarkers with diagnostic, prognostic and/or therapeutic potential in low- and high-grade gliomas. For that purpose, we analyzed the correlation among radiological data, IDH1/2 mutations, gene expression profiling of multiple endocrine/metabolic elements in 25 tumor biopsies samples from patients (Age 48 ± 10-years/72%-men) clinically diagnosed with glioma (WHO2016). Initially, we used high resolution 31P and 1H magnetic resonance spectroscopy (MRS) in order to obtainthe quantification of 19 metabolites with a LCModel, while gene expression profiling was performed using qPCR of 19 genes related to energy metabolism. Moreover, IDH1/2 common mutation (IDH1R132H/IDH2R172H) was verified by immunohistochemistry and Sanger sequencing. Sequentially, all data was integrated using the mixOmics (R-package) allowing to build correlation network plot graphs and correlation maps to identify the most significant interactions, that were analyzed thereafter. Our results shown that the most frequent clinical features were intracranial hypertension and focal deficit. Remarkably, we found no differences between the metabolic or gene expression profiles in grade III vs IV glioma samples. However, there was a statistical significance or near-threshold correlation between some endocrine/metabolic patterns and IDH-mutation, where Alanine (4.7 ± 1.3% IDHw vs 2.5 ± 0.7 IDHmut), Glycine (2.7 ± 0.5% vs 1.6 ± 0.4%), Glycerophosphorylcholine (3.9 ± 0.4% vs 6.4 ± 0.9%) and Myo-inositol (4.9 ± 1.0% vs 11.9 ± 2.1%) were the most important biomarkers. Over expression of Lactate Dehydrogenase subunit-B (LDHB, 19 ± 3% vs 31 ± 6%) and Aconitase-1 (ACO1, 0.5 ± 0.1% vs 1.2 ± 0.3%) had also a significant or near-threshold relationship with IDH-mutation. Altogether, these results indicate that the endocrine-metabolic interaction patterns analyzed by this novel interactomic approach could be a useful tool to improve our knowledge of glioma behavior as well as being a potential source to identify novel biomarkers and therapeutic targets in order to tackle this pathology.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more